Thursday, June 13, 2013

Taro initiates Bioequivalence study for generic version of GlaxoSmithkline's Bactroban cream

Taro which already sells a generic copy of Bactroban (Mupirocin Calcium) ointment is also looking to launch generic versions of Bactroban cream. Although the patent on Bactroban cream expires in October 2014, but an Indian generic company - Glenmark has already received the final USFDA approval (January 2013) and was expected to initiate selling generic copies in the US.

Taro expects the bio-equivalence trial to complete in February 2014, hence Taro may be expected to reach the market in 2015 or 2016, until then Glenmark may continue to be sole generic player on the market. 

 In 2012, Bactroban cream generated approximately $55m in annual sales in the US. Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S. aureus and S. pyogenes

Enter your email address:


Delivered by FeedBurner